Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSPPT2-TT: Amlodipine Folic Acid for Stroke Prevention in Hypertensive Patients with MTHFR 677 TT Genotype
NCT04974151Phase 4Recruiting
- Sponsor
- Shenzhen Ausa Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of amlodipine + folic acid, 5-MTHF in hypertension (HTN), hyperhomocysteinemia, sponsored by Shenzhen Ausa Pharmaceutical. Started Aug 2024; status: recruiting.
02
Drugs
amlodipine + folic acid5-MTHF
03
Conditions
hypertension (HTN)hyperhomocysteinemia
Beyond the preview
Go deeper on NCT04974151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974151.